Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Dysfunctional Uterine Bleeding Companies

ID: MRFR/Pharma/3264-HCR
110 Pages
Vikita Thakur
Last Updated: February 16, 2025
"Dysfunctional Uterine Bleeding" (DUB) is a medical term that refers to abnormal uterine bleeding that is not associated with any structural abnormalities or underlying medical conditions. Instead, it is often attributed to hormonal imbalances that disrupt the normal menstrual cycle. Companies that may be involved in addressing or providing solutions for Dysfunctional Uterine Bleeding typically operate in the healthcare and pharmaceutical sectors.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Dysfunctional Uterine Bleeding Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.89%
2024 Market Size$ 1.86 Billion
2025 Market Size$ 1.97 Billion
2035 Market Size$ 3.49 Billion
Key Players
AbbVie
Bayer
Hologic
Merck
Pfizer
Teva
Trends
  • Personalized Treatment Approaches
  • Telemedicine Integration
  • Innovative Therapeutic Developments
Opportunities
  • Increased Awareness and Education
  • Advancements in Medical Technology
  • Rising Prevalence of Uterine Disorders
Summary Table of Contents Segmentation Methodology Download PDF

Top Industry Leaders in the Dysfunctional Uterine Bleeding Market

Dysfunctional Uterine Bleeding Key Companies
 
Latest Dysfunctional Uterine Bleeding Companies Update

Myovant's Ormeloxifene (SER-120) Phase 3 Trials is conducting two Phase 3 trials (MUSE 1 and MUSE 2) evaluating the efficacy and safety of Ormeloxifene (SER-120) for the treatment of DUB caused by fibroids. Positive results could significantly impact the market by offering a non-hormonal therapy option.

Minerva Surgical's Sonata® System received FDA approval for its Sonata® System, a minimally invasive device for endometrial ablation used in the treatment of heavy menstrual bleeding and DUB. This technology offers an alternative to traditional hysterectomy for some patients.

List of Dysfunctional Uterine Bleeding Key Companies in the Market

  • Braun Melsungen AG (Germany)
  • Hologic Inc. (U.S.)
  • Karl Storz Gmbh & Co. KG (Germany)
  • Medgyn Products Inc.
  • Olympus (Japan)
  • Richard Wolf GmbH (Germany)
  • Stryker (U.S.)
  • Xion Medical GmbH (Germany)
  • Cadila Pharmaceuticals Ltd. (India)
  • Torrent Phamraceuticals (India)

Related Reports

No regional reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035